What is the role of anti-IL-33 therapy (ANB020) in the treatment of atopic dermatitis (eczema)?

Updated: Aug 02, 2019
  • Author: Brian S Kim, MD, MTR, FAAD; Chief Editor: William D James, MD  more...
  • Print

IL-33 is an epithelial cell–derived cytokine that promotes downstream type 2 cytokine (eg, IL-4) responses by acting on multiple cell types, including Th2 cells, basophils, and ILC2s. A 2017 small phase 2a study using a therapeutic anti-IL-33 antibody (ANB020) demonstrated promising results in terms of EASI as early as at day 15. [52] However, larger randomized trials are required to fully determine the efficacy of this drug.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!